Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.

about

MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.

P2860

Q38755690-6FD000E5-938A-43AE-9708-43F0B5A3E0AF Q39004638-13AEEE4A-5E3C-46EE-A7B1-63501D379530

P2860

Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.

Item

http://www.wikidata.org/entity/Q40883043

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Foscarnet, zidovudine and dolu ...... apy: A case-series experience.

@en

type

Item

label

Foscarnet, zidovudine and dolu ...... apy: A case-series experience.

@en

prefLabel

Foscarnet, zidovudine and dolu ...... apy: A case-series experience.

@en

P1476

Foscarnet, zidovudine and dolu ...... apy: A case-series experience.

@en

P2093

Christophe Rioux

http://www.w3.org/2001/XMLSchema#string

Claire Auge-Courtoi

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Papot

http://www.w3.org/2001/XMLSchema#string

Florence Michard

http://www.w3.org/2001/XMLSchema#string

Yazdan Yazdanpanah

http://www.w3.org/2001/XMLSchema#string

P2860

Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance

Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.

Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.

Foscarnet nephrotoxicity: mechanism, incidence and prevention.

P304

1204-1210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JMV.24442

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte Charpentier

P577

2015-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26636432

http://www.w3.org/2001/XMLSchema#string

Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.

about

P2860

P2860

Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698